Akoya Biosciences’ Multiplex Immunofluorescence Technology for Cancer Research to be Featured at AACR 2019

On March 26, 2019 Akoya Biosciences, Inc., reported that data from its new line of multiplex immunofluorescence imaging platforms for high-parameter, spatially resolved biomarker analysis will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019. The meeting runs March 29 – April 3, 2019 in Atlanta, Georgia (Press release, Akoya Biosciences, MAR 26, 2019, View Source [SID1234534643]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will feature data from its new products in an Exhibitor Spotlight Theater presentation on Sunday, March 31, from 1:30-2:30 PM titled "Pushing the frontiers of immuno-oncology with multiplex immunofluorescence" with speakers David Rimm, MD, PhD, Professor of Pathology at Yale University School of Medicine and Julia Kennedy-Darling, PhD, Director of R&D at Akoya Biosciences. During the presentation, Dr. Rimm will discuss the results from a Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study) which assessed the reproducibility of Akoya’s automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow.

"The exciting results from our MITRE Study demonstrate that multiplexed immunofluorescence methods can be analytically robust enough to support translation into large scale trials and eventual clinical practice," said Clifford Hoyt, Vice President, Translational and Scientific Affairs at Akoya Biosciences. "In addition, we’ve provided a template for other investigative teams to use for assessing reproducibility of their multiplex panels. The next step in this multi-site project will be to apply this assay retrospectively to discover and develop predictive biomarkers for PD1 and PDL1 therapies. We at Akoya are very grateful for the significant technical and scientific contributions from participants, who share a mission to ultimately deploy these methods for the benefit of patients."

Accepted abstracts will feature data from the new CODEX System, which can transform existing fluorescence microscopes into high-quality multiplexed tissue imagers for more than 40 biomarkers. Data will also be presented from the company’s new Phenoptics 2.0 platform, which includes the Vectra Polaris imaging system, Opal detection reagents, and inForm analysis software. Phenoptics 2.0 now also includes the company’s proprietary MOTiF technology, which acquires multispectral images on whole-slide tissue sections using up to seven colors simultaneously, and at speeds 20 times faster than previously possible.

Akoya’s abstracts include:

Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study) – Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow
Poster # 9, Section 42, Presentation LB318
Wednesday, April 3 from 8 AM to 12 PM
Highly multiplexed single-cell spatial analysis of tissue specimens using CODEX
Poster #3, Section 20, Presentation 490
Sunday, March 31 from 1 to 5 PM
Quantifying tumor heterogeneity and mapping complex immune cell interactions with high-throughput, 7-color multispectral slide scans
Poster #30, Section 6, Presentation 153
Sunday, March 31 from 1 to 5 PM
In addition, several leading pharmaceutical companies and academic medical centers will be presenting data from studies using the company’s multiplex immunofluorescence technology including:

Tumor heterogeneity and its impact on immunoprofiling data: Whole tumor vs regions of interest (ROI) analysis of multiplex immunofluorescence in four carcinoma types
Poster #4, Section 20, Presentation 491
Sunday, March 31 from 1 to 5 PM
Impact of the spatial analysis of tumor-associated lymphocytes and tumor-associated macrophages on recurrence at early stage of non-small cell lung carcinoma
Poster #7, Section 9, Presentation 1180
Monday, April 1 from 8 AM to 12 PM
Multiplexed immunofluorescence and multispectral imaging-based quantification of tumor and immune cell populations reveals spatial relationships in oral cavity squamous cell carcinoma
Poster #4, Section 7, Presentation 1132
Monday, April 1 from 8 AM to 12 PM
IL17 signaling modulates tumor microenvironment in pancreatic cancer
Poster #29, Section 3, Presentation 4575
Wednesday, April 3 from 8 AM to 12 PM
The company will also be providing demos in its booth (#4243) on Tuesday afternoon, April 2. For specific topics and times, see: View Source

Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day

On March 26, 2019 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the treatment of cancer, reported to present insights into the science behind tumor defense mechanisms and the company’s novel programmed T cell therapy programs in development utilizing targeted, modular approaches designed to address these mechanisms at its inaugural R&D Day, in New York (Press release, Autolus, MAR 26, 2019, View Source [SID1234534687]). In addition, the company plans to provide an update on its AUTO3 program in pediatric acute lymphocytic leukemia (pALL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AUTO3 is the first dual-targeting CD19 and CD22 programmed T cell therapy in development for both pALL and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Updated data from the ongoing AMELIA Phase 1/2 study in pALL demonstrates that 6 out of 6 (100%) patients treated at the highest dose (³3 x106/kg) achieved minimal residual disease (MRD) negative complete responses (CR). Ongoing MRD negative CR remissions were noted in 4 out of 6 (67%) patients, with duration of up to 10 months as of February 2019, the date of latest data follow-up. There have been no reported CD19 or CD22 negative relapses in CAR T naïve patients. Data also showed that AUTO3 continues to be generally well tolerated with no ³ Grade 3 CRS, no ICU admission, and no pressors or critical care support for CRS required. The Phase 2 portion of the study is expected to start in the second half of 2019. For more information about this trial and the inclusion criteria, visit www.ClinicalTrials.gov (NCT03289455).

"We are pleased to be hosting our inaugural R&D day, providing a unique opportunity to present an in-depth overview of our differentiated technology, multiple programs, market opportunities and the significant pipeline progress we have achieved, to date," stated Dr. Christian Itin, chairman and chief executive officer of Autolus. "We expect to report data on all of our active clinical programs at key medical conferences during 2019. Additionally, over the coming months, we expect to move two programs into registrational trials and to progress our next generation programs toward the clinic."

Today’s R&D program will include the following presentations:

Dr. Christian Itin, Chairman and Chief Executive Officer of Autolus – Welcome and Overview

Dr. Samir N. Khleif, Director of the Loop Immuno-Oncology Lab and Biomedical Scholar and Professor of Oncology, Georgetown University Medical Center – Immunotherapy, A Combinatorial Approach for Success

Dr. Muhammad Al-Hajj, Senior Vice President, Translational Sciences of Autolus – Translational Aspects of Tumor Heterogeneity

Dr. Martin Pule, Chief Scientific Officer and Founder of Autolus and Clinical Senior Lecturer at University College London Cancer Institute – Tackling Solid Tumors: A Modular Approach to T Cell Programming

Dr. Vijay Peddareddigari, Chief Medical Officer of Autolus – Clinical Update: Current and Next Generation Programs

LOGO

A live video webcast of the event will be available beginning at 8:00 am ET today on the Events section of Autolus’ website: View Source An archived replay will be available on the website for one year.

About AUTO3

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in two clinical studies, AMELIA and ALEXANDER.

AMELIA is a single-arm, open label, multi-center Phase 1/2 clinical trial of AUTO3 in patients up to 24 years of age with high-risk relapsed or refractory B-lineage. The trial is also enrolling patients who previously received CD19 or CD22 targeting therapies including other CAR T cell therapy. The purpose of this study is to test the safety and efficacy, including the complete remission rate or minimal residual disease (MRD) negative response, of AUTO3. Autolus expects to enroll up to 54 patients in this trial.

ALEXANDER is a single-arm, open label, multi-center Phase 1/2 clinical trial of AUTO3 in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). The purpose of this study is to test the safety and efficacy, including the overall response rate as per Lugano criteria, of AUTO3 followed by limited duration of consolidation with anti-PD1 antibody. Autolus expects to enroll up to 120 patients in this trial.

For more information about these trials and the inclusion criteria, visit www.ClinicalTrials.gov.

Integral Molecular to Present Claudin 6 MAbs, a Therapeutic Asset for Solid Tumors, at Annual AACR Conference

On March 26, 2019 Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, reported that it will showcase updated data on its discovery of highly specific Claudin 6 MAbs at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) conference in Atlanta on Monday, April 1 (Press release, Integral Molecular, MAR 26, 2019, View Source [SID1234534628]). Claudin 6 is an established membrane protein target expressed in multiple cancers, including ovarian and gastric tumors, and absent from healthy adult tissues. Until now, the structural complexity of Claudin 6 and its similarity to proteins expressed on healthy tissue have limited its exploitation for targeted oncology therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is a strong need for therapeutic monoclonal antibodies that can provide more specific and less toxic treatments for ovarian cancer," said Ross Chambers, VP of Antibody Discovery. "Our lead antibody, isolated using our MPS Antibody Discovery platform, shows best-in-class Claudin 6 specificity. We are currently looking for partners to further develop these exciting assets."

Integral Molecular’s MPS Antibody Discovery platform encompasses a comprehensive technology suite that overcomes the obstacles of working with highly conserved and structurally complex membrane protein targets, like Claudin 6. This suite includes antigen engineering and presentation on Lipoparticles, immunization of divergent species, and the use of B-cell cloning to recover rare antibodies. Integral Molecular is currently isolating MAbs against dozens of membrane protein targets and welcomes antibody licensing opportunities and discovery partnerships.

Tarveda Therapeutics to Present Nonclinical Data on PEN-221 in Combination with Epigenetic Modulation at the 2019 AACR Annual Meeting

On March 26, 2019 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins) for the treatment of patients with a wide range of solid tumors, reported that the company will present nonclinical data on PEN-221 at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, occurring March 29 – April 3, 2019 in Atlanta, GA (Press release, Tarveda Therapeutics, MAR 26, 2019, View Source [SID1234534644]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PEN-221 is a miniature drug conjugate designed to rapidly penetrate deep into solid tumors where it is highly selective for somatostatin receptor 2 (SSTR2) and accumulates its potent DM1 cytotoxic payload. The presenter will demonstrate the effectiveness of PEN-221 in combination with epigenetic modulation by an HDAC inhibitor in nonclinical models of human cancer. The data show that an HDAC inhibitor increases the tumor expression of SSTR2 with synergy of efficacy.

Details of the poster presentation are as follows:

Title: Epigenetic modulation of SSTR2 expression provides the potential to broaden PEN-221 treatment population
Date: Tuesday, April 2, 2019
Time: 1:00pm Eastern Time
Location: Georgia World Congress Center, Atlanta, GA

Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted Immunotherapies

On March 26, 2019 Akrevia Therapeutics, a privately held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, and City of Hope, an independent research and treatment center for cancer, diabetes and other life-threatening diseases, reported that they have entered into an exclusive licensing agreement that will allow Akrevia to utilize innovative technology to engineer potent immune-activating cytokines that can be selectively activated in the tumor microenvironment (Press release, Akrevia Therapeutics, MAR 26, 2019, View Source [SID1234554019]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The tumor microenvironment has distinct physiological characteristics that can be exploited to help develop tools to deliver therapies that are more precise and potent than existing treatments. The new technology, licensed from the lab of John Williams, Ph.D., at City of Hope, is suited to a broad spectrum of cytokines – molecules for which current tumor activation approaches are not applicable. This novel Switchblade allows inactivated proteins to "flick open" at the point of attack, releasing potent anti-tumor agents precisely where they are needed, thus maximizing efficacy and minimizing the peripheral side effects that limit current cytokine therapies. This new platform can be applied to other highly potent biologic architectures, including diverse cytokine family members, chemokines and agonistic immune modulators which to date have proved intractable in clinical development. This new technology will augment Akrevia’s existing Aklusion platform technologies, and augments the existing technology previously licensed from City of Hope.

"Cytokines have immense promise as highly potent cancer immunotherapeutics, with well-understood biology – but their extreme potency and lack of tumor targeting have thwarted attempts to exploit this clinically," said Tim Clackson, Ph.D., president and executive vice president, R&D, Akrevia Therapeutics. "The new technology licensed from City of Hope will substantially complement our current platform portfolio, providing the ability to target tumor activation of the full range of potent, immune-stimulating molecules. Akrevia will use the newly licensed technology to aggressively advance our pipeline and build towards the next generation of targeted cancer treatments."

Under the agreement, Akrevia gains exclusive commercial rights for application of the technology to the development of proprietary products. City of Hope, internationally recognized for pioneering technology that enabled the creation of numerous breakthrough cancer drugs, developed this technology to help investigators and researchers shield their selected antibodies for targeted therapies and to improve drug delivery. The nonprofit institution is working to improve precision medicine for all patients.

"At City of Hope, our research teams focus on rapidly developing technologies that can quickly move from laboratory research to clinical treatment," said Williams, professor of Molecular Medicine, City of Hope. "Our team has developed a novel approach to unlock the potential of multiple important immuno-oncology mechanisms to deliver potent, targeted agents to patients. We look forward to our continued collaboration with Akrevia to harness the therapeutic potential of this technology with the goal of improving treatment for patients."